Emily Kaiser Maharjan

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants.

At ASRS 2022, Dr Sally Ong presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicentre Study.” Here she shares the biggest takeaways.

The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.

Dr Justis P. Ehlers dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.

KALAHARI study update; novel surgical approaches for progressive retinal detachments; and a new risk is identified for CST fluctuations.

Metformin may provide AMD protection; DAVIO presents positive 12-month results; TOWER study reveals new imaging index for AMD.

Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.

Dr Dilsher Dhoot discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.

Dr Steven Yeh provides a brief overview of available therapies for noninfectious uveitis and uveitis macular oedema.

Dr Aleksandra Rachitskaya discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.

While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.

Dr David Boyer discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.

Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Dr Sunir J. Garg explains how retinal surgeons can remove the vitreous gel with more efficiency.

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Dr Karl Csaky and Dr Fredrick Ferris III identified in 2007—Dr Csaky reinforces the importance of preserving the central retinal tissue.

Via four cases, Dr Harry Flynn describes a variety of endophthalmitis management options for retinal surgeons.

Dr Sally Tucker of Ora Europe walks through the clinical trial pathway, describing how Ora addresses complexities to make the path as efficient as possible.

Dr Yasha S. Modi discusses his best tips and tricks for finding and diagnosing infectious uveitis.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity and vessel diameter with a new prototype.

Dr Carlos Quezada Ruiz, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

Prof. Anat Loewenstein discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular oedema.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

Dr Jennifer I. Lim reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular oedema.

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

Dr David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

At ARVO 2022, Dr Jason S. Slakter presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

An end-of-week review of what happened in ophthalmology from April 9-April 15.

Dr Lisa Nijm advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.